人肿瘤浸润白细胞（CD4+CD8+ T cell) 表型分析

靶点 ：human tumor infiltrating CD4+CD8+T cell

宿主 ：Recombinant

适应物种 ：Human

应用范围 ：Flow cytometry

人肿瘤浸润白细胞（CD4+CD8+ TIL）表型分析流式抗体组合

肿瘤浸润白细胞（Tumor-infiltrating Leukocytes）表型分析是了解实体肿瘤内部免疫细胞组成及其对肿瘤发展影响的重要手段。但由于TIL含量稀少，检测信号容易被淹没在背景噪声中，给TIL分析带来极大困难。

美天旎为TIL细胞表型分析特别优化的流式抗体组合令检测更容易，且完全基于重组表达的REAfinity抗体真正实现无背景的TIL流式分析：

• 基因工程令FcγR突变，无需使用FcγR阻断也可避免非特异结合；
• 只需一种IgG同型对照；
• 批次间高度一致，令结果可重复；

应用举例
人原发卵巢肿瘤经gentleMACS Octo八通道组织解离器和Tumor Dissociation kit,human解离后，使用REAlease CD4/CD8 (TIL) MicroBeads, human 进行富集。将富集后的CD4+CD8肿瘤浸润T细胞采用如下REAfinity流式抗体组合进行免疫表型分析。
 

Specificity	Clone	Purpose	Fluorochrome	Detection filter	Product No.
CD3	REA613	T cell	FITC	525/50	130-113-138
CD4	REA623	CD4+ T cell	PerCP-Vio 770	725/40	130-113-228
CD8	REA734	CD8+ T cell	APC-Vio 770	785/62	130-110-681
CD39	REA739	Activation marker	PE-Vio 615	615/20	130-110-656
CD279(PD-1)	REA1165	Activation marker	PE	579/34	130-120-382
CD366 (TIM-3)	REA635	Activation marker	PE-Vio 770	785/62	130-121-334
CD137	REA765	Activation marker	APC	667/30	130-110-764

典型数据展示
Flow cytometric analysis of a human ovarian tumor sample. First, subsets of CD3⁺ T cells (A) were gated based on expression of CD4 and CD8 (B). The tumor-specific subpopulations CD279 (PD1)^hi CD366 (TIM-)⁺ CD39⁺ CD8⁺ T cells and CD279 (PD1)⁺ CD39⁺ CD137⁺ CD4⁺ T cells were identified based on expression of different activation markers (PD-1, TIM-3, CD39, and CD137) within CD4⁺ and CD8⁺ T cells (C−F).


详细信息请登录美天旎官网肿瘤微环境流式检测应用页面
Immunophenotyping of tumor-specific CD4⁺and CD8⁺ T cells from a human ovarian tumor using flow cytometry